美国芝加哥当地时间2025年5月30日至6月3日，一年一度的美国临床肿瘤学会（ASCO）年将盛大开启！作为肿瘤领域的年度盛会，其将一如既往地带来最前沿的肿瘤研究进展与诊疗理念，备受领域关注！当前，ASCO官网发布了2025 ASCO年会的摘要标题，【肿瘤资讯】特此整理胃食管/肝胆胰肿瘤领域的重磅研究，带大家先睹为快！
全体大会
摘要号：LBA5
报告人：Yelena Y. Janjigian, MD | Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center
英文标题：Event-free survival (EFS) in MATTERHORN: A randomized, phase 3 study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel chemotherapy (FLOT) in resectable gastric/gastroesophageal junction cancer (GC/GEJC).
中文标题：MATTERHORN研究的无事件生存期（EFS）结果：一项在可切除胃/胃食管结合部癌（GC/GEJC）中评估度伐利尤单抗联合氟尿嘧啶、亚叶酸、奥沙利铂和多西他赛化疗（FLOT）的随机3期研究。
口头报告
消化道肿瘤——胃食管、胰腺、肝胆肿瘤
摘要号：4000
报告人：Ronan Joseph Kelly | Charles A. Sammons Cancer Center at Baylor University Medical Center
英文标题：Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): First results of overall survival (OS) from CheckMate 577.
中文标题：辅助纳武利尤单抗用于新辅助放化疗（CRT）后切除的食管癌或胃食管结合部癌（EC/GEJC）：CheckMate 577研究的首次总生存期（OS）结果发布
摘要号：4001
报告人：Sun Young Rha | Yonsei Cancer Center, Yonsei University College of Medicine
英文标题：Lenvatinib plus pembrolizumab and chemotherapy versus chemotherapy in advanced, metastatic gastroesophageal adenocarcinoma: The phase 3, randomized LEAP-015 study.
中文标题：仑伐替尼联合帕博利珠单抗及化疗对比化疗治疗晚期转移性胃食管腺癌的3期随机研究LEAP-015
摘要号：LBA4002
报告人：Kohei Shitara | National Cancer Center Hospital East
英文标题：Trastuzumab deruxtecan (T-DXd) vs ramucirumab (RAM) + paclitaxel (PTX) in second-line treatment of patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) unresectable/metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA): Primary analysis of the randomized, phase 3 DESTINY-Gastric04 study.
中文标题：德曲妥珠单抗（T-DXd）对比雷莫西尤单抗（RAM）联合紫杉醇（PTX）二线治疗人表皮生长因子受体2阳性（HER2+）不可切除/转移性胃癌（GC）或胃食管结合部腺癌（GEJA）患者的疗效比较：随机、III期DESTINY-Gastric04研究的初步分析结果
摘要号：4003
报告人：齐长松 | 北京大学肿瘤医院
英文标题：Claudin18.2-specific CAR T cells (Satri-cel) versus treatment of physician's choice (TPC) for previously treated advanced gastric or gastroesophageal junction cancer (G/GEJC): Primary results from a randomized, open-label, phase II trial (CT041-ST-01).
中文标题：靶向Claudin18.2 CAR-T细胞（Satri-cel）疗法对比医生选择治疗方案（TPC）用于经治晚期胃癌或胃食管结合部癌（G/GEJC）的疗效：一项随机、开放标签II期临床试验（CT041-ST-01）的初步结果
摘要号：LBA4004
报告人：Michele Reni | Department of Medical Oncology, Pancreas Translational and Clinical Research Center, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University
英文标题：Results of a randomized phase III trial of pre-operative chemotherapy with mFOLFIRINOX or PAXG regimen for stage I-III pancreatic ductal adenocarcinoma.
中文标题：术前mFOLFIRINOX或PAXG方案化疗用于I-III期胰腺导管腺癌的随机III期临床试验结果
摘要号：LBA4005
报告人：Vincent J. Picozzi | Virginia Mason Medical Center
英文标题：PANOVA-3: Phase 3 study of tumor treating fields (TTFields) with gemcitabine and nab-paclitaxel for locally advanced pancreatic ductal adenocarcinoma (LA-PAC).
中文标题：PANOVA-3：肿瘤治疗电场（TTFields）联合吉西他滨和白蛋白结合型紫杉醇治疗局部晚期胰腺导管腺癌（LA-PAC）的3期研究
摘要号： 4006
报告人：Devalingam Mahalingam | Robert H. Lurie Comprehensive Cancer Center, Northwestern University
英文标题：Preliminary results from the randomized phase 2 study (1801 part 3B) of elraglusib in combination with gemcitabine/nab-paclitaxel (GnP) versus GnP alone in patients (pts) with previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC).
中文标题：Elraglusib联合吉西他滨/白蛋白结合型紫杉醇（GnP）对比单纯GnP方案治疗初治转移性胰腺导管腺癌（mPDAC）患者的随机2期研究（1801 part 3B）初步结果
摘要号：4007
报告人：Reena Engineer | Tata Memorial Centre (HBNI)
英文标题：A phase III randomized clinical trial evaluating perioperative therapy (neoadjuvant chemotherapy versus chemoradiotherapy) in locally advanced gallbladder cancers (POLCAGB).
中文标题：POLCAGB研究：局部晚期胆囊癌围手术期治疗（新辅助化疗对比放化疗）的III期随机临床试验
摘要号： 4008
报告人：Thorsten Oliver Goetze | Institute of Clinical Cancer Research (IKF), Krankenhaus Nordwest, UCT-University Cancer Center
英文标题：Neoadjuvant chemotherapy with gemcitabine plus cisplatin followed by radical liver resection versus immediate radical liver resection alone followed adjuvant therapy in biliary tract cancer: Final results from the phase III AIO/CALGP/ACO-GAIN-Trial.
中文标题：吉西他滨联合顺铂新辅助化疗后根治性肝切除术对比直接根治性肝切除术联合辅助治疗用于胆道癌的III期临床研究（AIO/CALGP/ACO-GAIN试验）最终结果
快速口头报告
消化道肿瘤——胃食管、胰腺、肝胆肿瘤
摘要号：LBA4012
报告人：沈琳 | 北京大学肿瘤医院
英文标题：Disitamab vedotin (DV) plus toripalimab (Tor) and chemotherapy (C)/trastuzumab (Tra) as first-line (1L) treatment of patients (pts) with HER2-expressing locally advanced or metastatic (la/m) gastric cancer.
中文标题：维迪西妥单抗联合特瑞普利单抗及化疗/曲妥珠单抗一线治疗HER2表达局部晚期或转移性胃癌的临床研究
摘要号：4013
报告人：Elena Elimova | Princess Margaret Cancer Centre
英文标题：Long-term outcomes and overall survival (OS) for zanidatamab + chemotherapy in HER2-positive (HER2+) advanced or metastatic gastroesophageal adenocarcinoma (mGEA): 4-year follow-up of a phase 2 trial.
中文标题：HER2阳性晚期或转移性胃食管腺癌（mGEA）患者接受泽尼达妥单抗联合化疗的长期预后和总生存期（OS）：一项II期临床试验的4年随访结果
摘要号：4014
报告人：Jens Hoeppner | University of Bielefeld, University Medical Center OWL, Campus Hospital Lippe
英文标题：Recurrence patterns in the prospective, randomized, controlled, multicenter phase III ESOPEC trial comparing perioperative chemotherapy with preoperative chemoradiotherapy in patients with esophageal adenocarcinoma.
中文标题：前瞻性、随机对照、多中心III期ESOPEC试验中食管腺癌患者围手术期化疗对比术前放化疗的复发模式分析
摘要号：4015
报告人：彭浩欣 | 北京大学肿瘤医院
英文标题：Decoding the response and resistant features to the Claudin18.2-specific CAR-T cell CT041 in gastric cancer: A multi-omics exploratory biomarker analysis of the phase 1 clinical trial.
中文标题：解码胃癌对靶向Claudin18.2 CAR-T细胞疗法CT041的应答与耐药特征：一项1期临床试验的多组学生物标志物探索性分析
摘要号：4016
报告人：周军 | 北京大学肿瘤医院
英文标题：Cosiporfin sodium (DVDMS)-mediated photodynamic therapy (PDT) versus treatment of physician’s choice (TPC) in patients (pts) with advanced esophageal cancer (aEC): A phase III, randomized, open-label, multicenter trial.
中文标题：华卟啉钠（DVDMS）介导的光动力疗法（PDT）对比医生选择治疗方案（TPC）治疗晚期食管癌（aEC）患者的III期随机、开放标签、多中心临床试验
摘要号：4017
报告人：虞先濬 | 复旦大学附属肿瘤医院
英文标题：Claudin18.2 (CLDN18.2) expression and efficacy in pancreatic ductal adenocarcinoma (PDAC): Results from a phase I dose expansion cohort evaluating IBI343.
中文标题：Claudin18.2（CLDN18.2）在胰腺导管腺癌（PDAC）中的表达及疗效：基于IBI343 I期剂量扩展队列的研究结果
摘要号：4018
报告人：Robert William Lentz | Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz School of Medicine
英文标题：Clinical activity of EBC-129, a first-in class, anti N256-glycosylated CEACAM5 and CEACAM6 antibody-drug conjugate (ADC), in patients with pancreatic ductal adenocarcinoma (PDAC) in a phase 1 study.
中文标题：首创新药EBC-129（靶向N256糖基化CEACAM5/CEACAM6的抗体偶联药物）在胰腺导管腺癌（PDAC）患者中的临床活性：一项I期研究结果
摘要号：4019
报告人：Katherine M. Bever | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University
英文标题：10-year follow up of a phase 2 clinical trial of pembrolizumab (pembro) in microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) advanced solid tumors.
中文标题：帕博利珠单抗（pembro）治疗高度微卫星不稳定（MSI-H）/错配修复缺陷（dMMR）晚期实体瘤的II期临床试验10年随访结果
摘要号：4020
报告人：Amylou C. Dueck | Alliance Statistics and Data Management Center, Mayo Clinic
英文标题：Health-related quality of life (HRQOL) in the phase 3 trial of cabozantinib vs placebo for advanced neuroendocrine tumors (NET) after progression on prior therapy (CABINET, Alliance A021602).
中文标题：卡博替尼对比安慰剂治疗经治进展晚期神经内分泌肿瘤（NET）的III期临床试验（CABINET，Alliance A021602）中健康相关生活质量（HRQOL）结果分析
临床科学研讨会
摘要号：4009
报告人：Cindy Neuzillet | Department of Medical Oncology, Curie Institute
英文标题：Maintenance with OSE2101 plus FOLFIRI vs FOLFIRI alone after FOLFIRINOX (FFX) induction in patients (Pts) with advanced pancreatic ductal adenocarcinoma (aPDAC): Primary endpoint results of a randomized TEDOPAM GERCOR D17-01 PRODIGE 63 trial.
中文标题：晚期胰腺导管腺癌（aPDAC）患者FOLFIRINOX（FFX）诱导治疗后，OSE2101联合FOLFIRI对比单用FOLFIRI维持治疗的随机对照研究（TEDOPAM GERCOR D17-01 PRODIGE 63试验）主要终点结果公布
摘要号：4010
报告人：龚继芳 | 北京大学肿瘤医院
英文标题：Efficacy and safety of cafelkibart (LM-108), an anti-CCR8 monoclonal antibody, in combination with anti-PD-1 therapy in patients with pancreatic cancer: Results from phase 1/2 studies
中文标题：抗CCR8 单克隆抗体 cafelkibart (LM-108) 联合抗 PD-1 疗法治疗胰腺癌患者的疗效和安全性：1/2 期研究结果
摘要号： 4011
报告人：Ronan Andrew McLaughlin | Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre – University Health Network, University of Toronto
英文标题：NeoPancONE: GATA6 expression as a predictor of benefit to peri-operative modified FOLFIRINOX in resectable pancreatic adenocarcinoma (r-PDAC): A multicentre phase II study.
中文标题：NeoPancONE研究：GATA6表达作为可切除胰腺腺癌（r-PDAC）围手术期改良FOLFIRINOX方案疗效预测标志物的多中心II期临床研究
创新疗法——免疫
摘要号： 2503
报告人： Marina Baretti | Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
英文标题：A therapeutic vaccine for fibrolamellar hepatocellular carcinoma.
中文标题：纤维板层状肝细胞癌的治疗性疫苗
排版编辑：肿瘤资讯-AS
苏公网安备32059002004080号
